Page last updated: 2024-11-07

6-phenylhexyl isothiocyanate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

6-phenylhexyl isothiocyanate is an organic compound with the formula C13H17NS. It is a colorless liquid with a pungent odor. It is used as a reagent in organic synthesis, and is also found in some plants. The compound has been shown to have biological activity, including anticancer and anti-inflammatory effects. It is also a potent inhibitor of the enzyme carbonic anhydrase. The compound is studied for its potential therapeutic applications, particularly in the treatment of cancer and inflammation.'
```

Cross-References

ID SourceID
PubMed CID114757
CHEMBL ID461242
SCHEMBL ID7809
MeSH IDM0198187

Synonyms (21)

Synonym
(6-isothiocyanatohexyl)benzene
6-phenylhexyl isothiocyanate
133920-06-6
ccris 6850
benzene, (6-isothiocyanatohexyl)-
CHEMBL461242
phenylhexylisothiocyanate
6-isothiocyanatohexylbenzene
unii-pcb7wlt5zx
pcb7wlt5zx ,
FT-0621304
phenylhexyl isothiocyanate
benzene,(6-isothiocyanatohexyl)-
SCHEMBL7809
DTXSID3021146
bdbm50073713
J-006454
6-phenylhexylisothiocyanate
Q27452536
alpha-methyl-p-[1-oxo-2-isoindolinyl]-benzeneaceticacid
phenylhexyl isothiocyanate, 6-

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" Dose-response curves revealed that PEITC was significantly more toxic in tumorigenic and non-tumorigenic cells relative to PHITC."( Comparison of phenethyl and 6-phenylhexyl isothiocyanate-induced toxicity in rat esophageal cell lines with and without glutathione depletion.
Hudson, TS; Mallery, SR; Morse, MA; Stoner, GD; Young, H, 2005
)
0.62

Pharmacokinetics

ExcerptReferenceRelevance
"9 h, with an elimination half-life (T1/2e) of 21."( Disposition and pharmacokinetics of phenethyl isothiocyanate and 6-phenylhexyl isothiocyanate in F344 rats.
Chung, FL; Conaway, CC; Jiao, D; Kohri, T; Liebes, L, 1999
)
0.54

Dosage Studied

ExcerptRelevanceReference
" For both isothiocyanates, there were no statistically significant differences between dosing frequencies in inhibitory effects on tumor multiplicities and tumor incidences."( Effect of frequency of isothiocyanate administration on inhibition of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-induced pulmonary adenoma formation in A/J mice.
Amin, SG; Chung, FL; Eklind, KI; Morse, MA, 1992
)
0.28
" Dose-response curves revealed that PEITC was significantly more toxic in tumorigenic and non-tumorigenic cells relative to PHITC."( Comparison of phenethyl and 6-phenylhexyl isothiocyanate-induced toxicity in rat esophageal cell lines with and without glutathione depletion.
Hudson, TS; Mallery, SR; Morse, MA; Stoner, GD; Young, H, 2005
)
0.62
" ADM combined with PHI can diminish side effect and dosage of ADM."( [Effect of phenylhexyl isothiocyanate on adriamycin resistance of K562/A02 cell line].
Chen, BA; Cheng, J; Liu, DL; Lu, QY; Ma, XD; Yuang, P, 2009
)
0.35
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Macrophage migration inhibitory factorHomo sapiens (human)IC50 (µMol)4.20000.03803.09109.8000AID1198788
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (35)

Processvia Protein(s)Taxonomy
prostaglandin biosynthetic processMacrophage migration inhibitory factorHomo sapiens (human)
positive regulation of cytokine productionMacrophage migration inhibitory factorHomo sapiens (human)
negative regulation of mature B cell apoptotic processMacrophage migration inhibitory factorHomo sapiens (human)
inflammatory responseMacrophage migration inhibitory factorHomo sapiens (human)
cell surface receptor signaling pathwayMacrophage migration inhibitory factorHomo sapiens (human)
positive regulation of cell population proliferationMacrophage migration inhibitory factorHomo sapiens (human)
negative regulation of gene expressionMacrophage migration inhibitory factorHomo sapiens (human)
positive regulation of protein kinase A signalingMacrophage migration inhibitory factorHomo sapiens (human)
negative regulation of macrophage chemotaxisMacrophage migration inhibitory factorHomo sapiens (human)
carboxylic acid metabolic processMacrophage migration inhibitory factorHomo sapiens (human)
DNA damage response, signal transduction by p53 class mediatorMacrophage migration inhibitory factorHomo sapiens (human)
negative regulation of cell migrationMacrophage migration inhibitory factorHomo sapiens (human)
positive regulation of B cell proliferationMacrophage migration inhibitory factorHomo sapiens (human)
positive regulation of lipopolysaccharide-mediated signaling pathwayMacrophage migration inhibitory factorHomo sapiens (human)
positive regulation of tumor necrosis factor productionMacrophage migration inhibitory factorHomo sapiens (human)
negative regulation of myeloid cell apoptotic processMacrophage migration inhibitory factorHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylationMacrophage migration inhibitory factorHomo sapiens (human)
positive regulation of phosphorylationMacrophage migration inhibitory factorHomo sapiens (human)
regulation of macrophage activationMacrophage migration inhibitory factorHomo sapiens (human)
negative regulation of apoptotic processMacrophage migration inhibitory factorHomo sapiens (human)
negative regulation of DNA damage response, signal transduction by p53 class mediatorMacrophage migration inhibitory factorHomo sapiens (human)
innate immune responseMacrophage migration inhibitory factorHomo sapiens (human)
positive regulation of fibroblast proliferationMacrophage migration inhibitory factorHomo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationMacrophage migration inhibitory factorHomo sapiens (human)
positive chemotaxisMacrophage migration inhibitory factorHomo sapiens (human)
negative regulation of protein metabolic processMacrophage migration inhibitory factorHomo sapiens (human)
positive regulation of prostaglandin secretion involved in immune responseMacrophage migration inhibitory factorHomo sapiens (human)
positive regulation of myeloid leukocyte cytokine production involved in immune responseMacrophage migration inhibitory factorHomo sapiens (human)
protein homotrimerizationMacrophage migration inhibitory factorHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeMacrophage migration inhibitory factorHomo sapiens (human)
positive regulation of arachidonic acid secretionMacrophage migration inhibitory factorHomo sapiens (human)
cellular senescenceMacrophage migration inhibitory factorHomo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorMacrophage migration inhibitory factorHomo sapiens (human)
positive regulation of chemokine (C-X-C motif) ligand 2 productionMacrophage migration inhibitory factorHomo sapiens (human)
negative regulation of cellular senescenceMacrophage migration inhibitory factorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (8)

Processvia Protein(s)Taxonomy
protease bindingMacrophage migration inhibitory factorHomo sapiens (human)
dopachrome isomerase activityMacrophage migration inhibitory factorHomo sapiens (human)
cytokine activityMacrophage migration inhibitory factorHomo sapiens (human)
cytokine receptor bindingMacrophage migration inhibitory factorHomo sapiens (human)
protein bindingMacrophage migration inhibitory factorHomo sapiens (human)
chemoattractant activityMacrophage migration inhibitory factorHomo sapiens (human)
identical protein bindingMacrophage migration inhibitory factorHomo sapiens (human)
phenylpyruvate tautomerase activityMacrophage migration inhibitory factorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (11)

Processvia Protein(s)Taxonomy
extracellular regionMacrophage migration inhibitory factorHomo sapiens (human)
extracellular spaceMacrophage migration inhibitory factorHomo sapiens (human)
nucleoplasmMacrophage migration inhibitory factorHomo sapiens (human)
cytoplasmMacrophage migration inhibitory factorHomo sapiens (human)
cytosolMacrophage migration inhibitory factorHomo sapiens (human)
plasma membraneMacrophage migration inhibitory factorHomo sapiens (human)
cell surfaceMacrophage migration inhibitory factorHomo sapiens (human)
vesicleMacrophage migration inhibitory factorHomo sapiens (human)
secretory granule lumenMacrophage migration inhibitory factorHomo sapiens (human)
extracellular exosomeMacrophage migration inhibitory factorHomo sapiens (human)
ficolin-1-rich granule lumenMacrophage migration inhibitory factorHomo sapiens (human)
extracellular spaceMacrophage migration inhibitory factorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (18)

Assay IDTitleYearJournalArticle
AID412934Induction of apoptosis in human UACC-903 cells assessed as increase in caspase 3 activity after 24 hrs relative to control2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Synthesis and anticancer activity comparison of phenylalkyl isoselenocyanates with corresponding naturally occurring and synthetic isothiocyanates.
AID680703TP_TRANSPORTER: increase in Vinblastine intracellular accumulation (Daunomycin: 0.05 uM, Phenylhexyl isothiocyanate: 100 uM) in MCF-7/ADR cells2002Pharmaceutical research, Oct, Volume: 19, Issue:10
Effect of organic isothiocyanates on the P-glycoprotein- and MRP1-mediated transport of daunomycin and vinblastine.
AID412929Cytotoxicity against human PC-3 cells after 72 hrs by MTS assay2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Synthesis and anticancer activity comparison of phenylalkyl isoselenocyanates with corresponding naturally occurring and synthetic isothiocyanates.
AID412932Cytotoxicity against human UACC-903 cells assessed as decrease in cell viability after 24 hrs by MTS assay relative to control2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Synthesis and anticancer activity comparison of phenylalkyl isoselenocyanates with corresponding naturally occurring and synthetic isothiocyanates.
AID692256Induction of p53 R280K mutant depletion in human MDA-MB-231 cells at 10 uM by immunoblot analysis2011Journal of medicinal chemistry, Feb-10, Volume: 54, Issue:3
Selective depletion of mutant p53 by cancer chemopreventive isothiocyanates and their structure-activity relationships.
AID412927Cytotoxicity against human MDA-MB-231 cells after 72 hrs by MTS assay2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Synthesis and anticancer activity comparison of phenylalkyl isoselenocyanates with corresponding naturally occurring and synthetic isothiocyanates.
AID412928Cytotoxicity against human T98G cells after 72 hrs by MTS assay2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Synthesis and anticancer activity comparison of phenylalkyl isoselenocyanates with corresponding naturally occurring and synthetic isothiocyanates.
AID412937Antitumor activity in human UACC-903 cells xenografted in Harlan Sprague-Dawley athymic nude mouse assessed as reduction in tumor size at 2.5 uM, ip administered three times per week2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Synthesis and anticancer activity comparison of phenylalkyl isoselenocyanates with corresponding naturally occurring and synthetic isothiocyanates.
AID412939Toxicity in human UACC-903 cells xenografted in Harlan Sprague-Dawley athymic nude mouse assessed as effect on body weight at 2.5 uM, ip administered three times per week2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Synthesis and anticancer activity comparison of phenylalkyl isoselenocyanates with corresponding naturally occurring and synthetic isothiocyanates.
AID412931Cytotoxicity against human UACC-903 cells after 72 hrs by MTS assay2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Synthesis and anticancer activity comparison of phenylalkyl isoselenocyanates with corresponding naturally occurring and synthetic isothiocyanates.
AID681311TP_TRANSPORTER: increase in Vinblastine intracellular accumulation (Vinblastine: 0.05 uM, Phenylhexyl isothiocyanate: 100 uM) in PANC-1 cells2002Pharmaceutical research, Oct, Volume: 19, Issue:10
Effect of organic isothiocyanates on the P-glycoprotein- and MRP1-mediated transport of daunomycin and vinblastine.
AID412933Antiproliferative activity against human UACC-903 cells assessed as BrdU incorporation after 24 hrs by ELISA relative to control2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Synthesis and anticancer activity comparison of phenylalkyl isoselenocyanates with corresponding naturally occurring and synthetic isothiocyanates.
AID412936Antitumor activity in human UACC-903 cells xenografted in Harlan Sprague-Dawley athymic nude mouse assessed as reduction in tumor size at 0.76 uM, ip administered three times per week2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Synthesis and anticancer activity comparison of phenylalkyl isoselenocyanates with corresponding naturally occurring and synthetic isothiocyanates.
AID692255Induction of p53 G245C mutant depletion in human NCI-H596 cells at 20 uM by immunoblot analysis2011Journal of medicinal chemistry, Feb-10, Volume: 54, Issue:3
Selective depletion of mutant p53 by cancer chemopreventive isothiocyanates and their structure-activity relationships.
AID1198788Inhibition of macrophage migration inhibitory factor tautomerase activity in human Jurkat T cells using L-dopachrome methyl ester as substrate incubated for 30 mins prior to substrate addition measured for 2 mins by spectrophotometric analysis2015European journal of medicinal chemistry, Mar-26, Volume: 93Multiple binding modes of isothiocyanates that inhibit macrophage migration inhibitory factor.
AID412935Induction of apoptosis in human UACC-903 cells assessed as increase in caspase 7 activity after 24 hrs relative to control2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Synthesis and anticancer activity comparison of phenylalkyl isoselenocyanates with corresponding naturally occurring and synthetic isothiocyanates.
AID412940Cytotoxicity against human HT1080 cells after 72 hrs by MTS assay2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Synthesis and anticancer activity comparison of phenylalkyl isoselenocyanates with corresponding naturally occurring and synthetic isothiocyanates.
AID412930Cytotoxicity against human Caco-2 cells after 72 hrs by MTS assay2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Synthesis and anticancer activity comparison of phenylalkyl isoselenocyanates with corresponding naturally occurring and synthetic isothiocyanates.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (38)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's14 (36.84)18.2507
2000's13 (34.21)29.6817
2010's11 (28.95)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 10.69

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index10.69 (24.57)
Research Supply Index3.69 (2.92)
Research Growth Index4.38 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (10.69)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other39 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]